)
)
Allan Gobbs
Managing Partner,
ATEM Capital
Allan Gobbs is the Managing Partner at ATEM Capital, a New York-based Life Sciences venture firm. In recent years, Allan has seen five of his portfolio companies go public on NASDAQ, including notable names like Atea Pharmaceuticals, Marinus Pharmaceuticals, and Syndax Pharmaceuticals. Additionally, four of his portfolio companies have been successfully acquired, such as Tobira Therapeutics, which was bought by Allergan for up to $1.7 billion, and Amolyt Pharmaceuticals, AI-drug discovery peptide-based company acquired by AstraZeneca for up to $1.05 billion in July 2024.
Allan is also the CEO and Chairman of YCare, a digital health integrator in strategic partnership with Dell Technologies and InterSystems, and the Chairman of PGxAI, an AI-powered pharmacogenetics platform. He serves as the President of Virry Health, an AI-powered XR platform focused on tackling mental health conditions, and is a Board Member of Heos Machines, a 3D bioprinting startup. Prior to joining ATEM Capital, Allan was an investment banker at Barclays Capital and other financial institutions, where he advised on mergers, acquisitions, and capital market transactions totaling over $20 billion. He is also a member of the Forbes Business Council, the Private Directors Association, and serves on the Review Committee of the National Cancer Institute at the NIH.
Allan is also the CEO and Chairman of YCare, a digital health integrator in strategic partnership with Dell Technologies and InterSystems, and the Chairman of PGxAI, an AI-powered pharmacogenetics platform. He serves as the President of Virry Health, an AI-powered XR platform focused on tackling mental health conditions, and is a Board Member of Heos Machines, a 3D bioprinting startup. Prior to joining ATEM Capital, Allan was an investment banker at Barclays Capital and other financial institutions, where he advised on mergers, acquisitions, and capital market transactions totaling over $20 billion. He is also a member of the Forbes Business Council, the Private Directors Association, and serves on the Review Committee of the National Cancer Institute at the NIH.
Sessions
-
11-Dec-2024The AI Accelerator StageThe AI Startup Journey from Pre-Seed to Exit
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
)
)
-(1).png/fit-in/500x500/filters:no_upscale()){kind=logo}
){kind=logo}
){kind=logo}
)
.svg){kind=logo}
)
)
){kind=logo}
.jpg/fit-in/500x500/filters:no_upscale())
){kind=logo}
.jpg/fit-in/500x500/filters:no_upscale())
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())
